On Tuesday, Gilead Sciences, Inc (NASDAQ: GILD) opened higher 0.78% from the last session, before settling in for the closing price of $122.05. Price fluctuations for GILD have ranged from $86.08 to $124.61 over the past 52 weeks.
During the last 5-year period, the sales drop of Healthcare Sector giant was -38.13%. Company’s average yearly earnings per share was noted 76.67% at the time writing. With a float of $1.24 billion, this company’s outstanding shares have now reached $1.24 billion.
Gilead Sciences, Inc (GILD) Insider Activity
A key investor’s attitude towards the stock of the Drug Manufacturers – General industry is another important factor to consider. The insider ownership of Gilead Sciences, Inc is 0.19%, while institutional ownership is 88.98%. The most recent insider transaction that took place on Oct 28 ’25, was worth 1,193,926. In this transaction Chairman & CEO of this company sold 10,000 shares at a rate of $119.39, taking the stock ownership to the 581,203 shares. Before that another transaction happened on Oct 28 ’25, when Company’s Officer proposed sale 10,000 for $119.39, making the entire transaction worth $1,193,926.
Gilead Sciences, Inc (GILD) Earnings and Forecasts
If we go through the results of last quarter, which was made public on 12/31/2024, the company posted 1.9 earnings per share (EPS) for the quarter, besting the agreed prediction (set at 1.7) by 0.2. Wall Street market experts anticipate that the next fiscal year will bring earnings of 2.03 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 76.67% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 26.38% during the next five years compared to -38.13% drop over the previous five years of trading.
Gilead Sciences, Inc (NASDAQ: GILD) Trading Performance Indicators
Check out the current performance indicators for Gilead Sciences, Inc (GILD). In the past quarter, the stock posted a quick ratio of 1.17. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.26. Likewise, its price to free cash flow for the trailing twelve months is 16.29.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 6.45, a number that is poised to hit 1.93 in the next quarter and is forecasted to reach 8.66 in one year’s time.
Technical Analysis of Gilead Sciences, Inc (GILD)
Looking closely at Gilead Sciences, Inc (NASDAQ: GILD), its last 5-days average volume was 8.23 million, which is a jump from its year-to-date volume of 8.0 million. As of the previous 9 days, the stock’s Stochastic %D was 75.15%.
During the past 100 days, Gilead Sciences, Inc’s (GILD) raw stochastic average was set at 92.01%, which indicates a significant increase from 84.80% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 3.36 in the past 14 days, which was higher than the 2.66 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $116.01, while its 200-day Moving Average is $110.13. However, in the short run, Gilead Sciences, Inc’s stock first resistance to watch stands at $124.64. Second resistance stands at $126.27. The third major resistance level sits at $128.97. If the price goes on to break the first support level at $120.30, it is likely to go to the next support level at $117.60. Should the price break the second support level, the third support level stands at $115.97.
Gilead Sciences, Inc (NASDAQ: GILD) Key Stats
There are currently 1,240,807K shares outstanding in the company with a market cap of 152.62 billion. Presently, the company’s annual sales total 28,754 M according to its annual income of 480,000 K. Last quarter, the company’s sales amounted to 7,769 M and its income totaled 3,052 M.
